We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.075 | 2.00 | 2.15 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.82 | 6.9M |
Date | Subject | Author | Discuss |
---|---|---|---|
21/12/2017 07:34 | Adoring....Imm don’t have any control over the short term share price. | flavio_monteiro | |
21/12/2017 07:32 | Che7win.....the directors are good negotiators...they know the value of the p140 platform and have a lot of stock and option. Don’t worry we will be taken over for the right price. | flavio_monteiro | |
21/12/2017 07:31 | Now we know the price was dropped yesterday to give those 900’000 options grant price! | adorling | |
21/12/2017 07:29 | This is going to be taken over way too cheap if we don't move up to £10 soon... | che7win | |
21/12/2017 07:27 | RNS Options granted at a HIGH PRICE 153p to key staff. | flavio_monteiro | |
21/12/2017 07:25 | Last patient dosed, safety profile still good, means last evaluation and trial end is in no more than 28 days, ie. around 18th January. | hottingup | |
21/12/2017 07:17 | Fantastic news, we’re on our way. Talk about a manipulative tree shake yesterday lol Onwards & upwards with increased confidence. Price target short term before Q1 - 2018..270p imho | ny boy | |
21/12/2017 07:12 | Oh the irony of this rns today after the schenanighans (?) of the share price yesterday!!! | sportbilly1976 | |
21/12/2017 07:10 | Good bought more yesterday. | ashehzi | |
21/12/2017 07:09 | Continued robust safety record 12 months. No serious side effects.Nice | herschel k | |
21/12/2017 07:07 | Last patient has completed all doses | mr. t | |
20/12/2017 22:49 | PL, FA Cup & CL, basically the treble, which only United have done before. | ny boy | |
20/12/2017 22:08 | so what's left to win this season ? | arab3 | |
20/12/2017 22:02 | Yawn, egg cup, best not get too excited | ny boy | |
20/12/2017 22:01 | taxi for jose pmsl | arab3 | |
20/12/2017 20:34 | Greedfear, I doubt it but happy to leave a buy order in at 137p tomorrow | ny boy | |
20/12/2017 20:12 | Glaxo have a poor Lupus drug....and they sales of Benlista will dwindle when the far superior Lupuzor is approved by the FDA. The results of the phase 3 will follow shortly after the last patient is doses as the CRO is collecting each patient data as the 12 dosing phase is completed...I am expecting results by mid February. From a charting and technical perspective....we had a very positive candlestick today (hammer) so expecting further upside this week. | flavio_monteiro | |
20/12/2017 18:38 | Did not expect a retrace to 136p to happen within one day. I do expect a second test of 136p. | greedfear | |
20/12/2017 17:58 | All good, keep focused, the potential huge prize can co e in Q1 - 2018, a few got mugged today and a few more took their shares. | ny boy | |
20/12/2017 17:21 | After all that - close flat! | sportbilly1976 | |
20/12/2017 15:49 | Ashehzi...Shhhh. don't tell badger that, he thinks we all going to hell in a handcart here :) | hamhamham1 | |
20/12/2017 15:45 | Did warn yesterday, looks like panic selling and stop lossees have filled in a few big orders. should stabilise from here and head higher. Also its clear a few NOT IN THE KNOW have creeped on this BB and trying to infulence the price mischeviously - really quite shameful in one or two cases who are given 'air time' when it is obvious they have NO IDEA what IMM is about, best to ignore them. Much of IMM story still to unfold and if you got in the 140s/150s then good luck and hold on for the next phase. | divinessence |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions